SonoThera, a biotech startup, has raised $125 million to develop its ultrasound-mediated platform for delivering genetic medicines. The funding will support the company's proprietary technology that combines ultrasound delivery with payload engineering for DNA and RNA therapeutics, gene editing, and gene silencing approaches.
The platform uses focused ultrasound to temporarily permeabilize cell membranes, enabling targeted delivery of genetic payloads to specific tissues. This approach aims to address limitations of viral vectors and lipid nanoparticles, particularly for non-liver targets.
SonoThera plans to use the capital to advance its pipeline of preclinical programs and expand its technology platform. The company has not disclosed specific indications or clinical timelines at this stage, remaining in early-stage development.
The $125 million round represents significant investor confidence in ultrasound-mediated delivery as a potential alternative to established gene therapy vectors. The company faces competition from other non-viral delivery platforms as the genetic medicine field grows rapidly.
While the technology shows promise for tissue-specific delivery, it remains early-stage with no clinical data yet available. The approach will need to demonstrate safety and efficacy in human trials before reaching patients.